Assessment of reproducibility of creatinine measurement and MELD scoring in four liver transplant units in the UK

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 960-966

  Goulding, Carol ^a   Cholongitas, Evangelous ^a   Nair, Devi ^a   Kerry, Andrew ^a   Patch, David ^a   Akyol, Murat ^b   Walker, Simon ^b   Manas, Derek ^c   Mc Clure, David ^c   Smith, Liesl ^c   Jamieson, Neville ^d   Oberg, Ingela ^d   Cartwright, David ^d   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Creatinine; Liver transplant; MELD score; Organ allocation

Indexed keywords

BILIRUBIN; CREATININE;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER TRANSPLANTATION; MALE; MODEL FOR END STAGE LIVER DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; UNITED KINGDOM;

ADULT; AGED; BILIRUBIN; CREATININE; FEMALE; GREAT BRITAIN; HUMANS; IRELAND; KIDNEY; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; WAITING LISTS;

EID: 77649211943     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp556     Document Type: Article

References (25)

1. Brown RS, Lake JR. The survival impact of liver transplant in the MELD era, and the future for organ allocation and distribution. Am J Transplant 2005; 5: 203-204
2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96
3. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
4. Cholongitas E, Marrelli L, Shusang V, et al. A systematic review of the performance of the model for end stage liver disease in the setting of liver transplantation. Liver Transplant 2006; 12: 1049-1061
5. Freeman RB. MELD/PELD: one year later. Transplant Proc 2003; 35: 2425-2427
6. Freeman RB, Wiesner RH, Edwards E, et al. UNOS/OPTN Liver and Intestine Transplantation Committee. Liver Transplant 2004; 10: 7-15
7. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313
8. Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the MELD system; a prospective study from a single European centre. Am J Transplant 2006; 6: 1572-1577
9. De La Mata M, Cuende N, Huet J, et al. Model for end stage liver disease score based allocation of donors for liver transplantation; a Spanish multicentre experience. Transplantation 2006; 82: 1429-1435
10. Ravaioli M, Masetti M, Ridolfi L, et al. Laboratory test variability and model for end stage liver disease score calculation: Effect on liver allocation and proposal for adjustment. Transplantation 2007; 87: 919-924
11. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transplant 2007; 13: 523-529
12. Trotter JF, Brimhall B, Arjal R, et al. Specific laboratory methodologies achieve higher Model for End Stage Liver Disease (MELD) scores for patients listed for liver transplant. Liver Transplant 2004; 10: 995-1000
13. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008; 57: 252-257
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310
15. Fraley DS, Burr R, Bernardini J, et al. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int 1998; 54: 518-524
16. Lisman T, Van Leeuwen Y, Adelmeijer J, et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 2008; 1344-1351
17. Cholongitas E, Shusang V, Marelli L, et al. Renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-978
18. Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988; 39: 465-490
19. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-1953
20. Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores-a systematic bias. Am J Transplant 2007; 7: 685-692
21. Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after the introduction of the MELD score. JAMA 2008; 300: 2371-2378
22. Trotter JF, Olson J, Lefkowitz J, et al. Change of international normalised ratio (INR) and Model for End Stage Liver Disease (MELD) based on selection of clinical laboratories. Am J Transplant 2007; 7: 1624-1628
23. Tripodi A, Chantaranqkul V, Primiquani M, et al. The international normalized ratio for cirrhosis (INR (liver)) normalizes prothrombin time results for model of end stage liver disease calculation. Hepato-logy 2007; 46: 520-527
24. Bellest L, Eschwege V, Poupon R, et al. A modified international normalized ration as an effective way of prothrombin standardization in hepatology. Hepatology 2007; 46: 528-534
25. Heuman DM, Minas AA, Habib A, et al. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anti-coagulation therapy. Liver Transplant 2007; 13: 2-4